Filtered By:
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 5486 results found since Jan 2013.
Viruses, Vol. 15, Pages 1828: Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18 & ndash;60 and 60+ Age Cohorts
In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with over 85% NT seroconversion rates after complete vaccination course in participants who were seronegative at screening in both age groups: 18–60 and 60+. In participants who were seropositive at screening and had nAB titers below 1:256, a single vaccination led to a fourfold increase in nAB levels in 85.2% of cases. These findings indicate that CoviVac can be successfully used both for primary vaccination in a two-dose regimen and for booster vaccination as a single dose in individuals with reduced neutralizing antibody levels.
Source: Viruses - August 29, 2023 Category: Virology Authors: Ilya V. Gordeychuk Liubov I. Kozlovskaya Aleksandra A. Siniugina Nadezhda V. Yagovkina Vladimir I. Kuzubov Konstantin A. Zakharov Viktor P. Volok Maria S. Dodina Larissa V. Gmyl Natalya A. Korotina Rostislav D. Theodorovich Yulia I. Ulitina Dmitry I. Vovk Tags: Article Source Type: research
Erythema Nodosum Induced by the Pfizer- BioNTech Vaccine
Skinmed. 2023 Aug 28;21(3):198-199. eCollection 2023.ABSTRACTA 42-year-old man presented with a painful nodular dermatitis with 38.5°C fever and joint pain, which started overnight. The patient had taken the first dose of Pfizer-BioNTech (Comirnaty, INN-COVID-19 mRNA) vaccine 8 days ago. He denied any kind of recent infections, inflammatory conditions, malignancies, or drugs administration.PMID:37634106
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Dessyslava G Nikolaeva Ivan A Bogdanov Miroslava I Kadurina Nikolai K Tsankov Source Type: research
The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers
CONCLUSIONS: The prevalence of SIRVA is estimated at 3% in the adult working population. Signs and symptoms of SIRVA are variable in severity, localization and timing. Soft-tissue abnormalities is the most common clinical sign. This study contributes to clinician's knowledge on SIRVA, aiding in early recognition and treatment, which are imperative for prevention of persistent and severe shoulder pathology.PMID:37635003 | DOI:10.1016/j.vaccine.2023.08.043
Source: Vaccine - August 27, 2023 Category: Allergy & Immunology Authors: Esther R C Janssen Astrid Z van Montfoort Freek Hollman Frederik O Lambers Heerspink Source Type: research
Erythema Nodosum Induced by the Pfizer- BioNTech Vaccine
Skinmed. 2023 Aug 28;21(3):198-199. eCollection 2023.ABSTRACTA 42-year-old man presented with a painful nodular dermatitis with 38.5°C fever and joint pain, which started overnight. The patient had taken the first dose of Pfizer-BioNTech (Comirnaty, INN-COVID-19 mRNA) vaccine 8 days ago. He denied any kind of recent infections, inflammatory conditions, malignancies, or drugs administration.PMID:37634106
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Dessyslava G Nikolaeva Ivan A Bogdanov Miroslava I Kadurina Nikolai K Tsankov Source Type: research
The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers
CONCLUSIONS: The prevalence of SIRVA is estimated at 3% in the adult working population. Signs and symptoms of SIRVA are variable in severity, localization and timing. Soft-tissue abnormalities is the most common clinical sign. This study contributes to clinician's knowledge on SIRVA, aiding in early recognition and treatment, which are imperative for prevention of persistent and severe shoulder pathology.PMID:37635003 | DOI:10.1016/j.vaccine.2023.08.043
Source: Vaccine - August 27, 2023 Category: Allergy & Immunology Authors: Esther R C Janssen Astrid Z van Montfoort Freek Hollman Frederik O Lambers Heerspink Source Type: research
Erythema Nodosum Induced by the Pfizer- BioNTech Vaccine
Skinmed. 2023 Aug 28;21(3):198-199. eCollection 2023.ABSTRACTA 42-year-old man presented with a painful nodular dermatitis with 38.5°C fever and joint pain, which started overnight. The patient had taken the first dose of Pfizer-BioNTech (Comirnaty, INN-COVID-19 mRNA) vaccine 8 days ago. He denied any kind of recent infections, inflammatory conditions, malignancies, or drugs administration.PMID:37634106
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Dessyslava G Nikolaeva Ivan A Bogdanov Miroslava I Kadurina Nikolai K Tsankov Source Type: research
